Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | PPARA | Q07869 | 3/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487973 | 1.00 | CASP1 (0.62) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL4973400 | 1.00 | CASP1 (0.62) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL7810073 | 0.99 | CASP1 (0.61) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL7810068 | 0.99 | CASP1 (0.61) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL7309224 | 0.90 | PPARA (0.55) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL7309215 | 0.90 | PPARA (0.55) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL7564546 | 0.89 | KYNU (0.58) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL6576404 | 0.89 | KYNU (0.58) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL4968729 | 0.89 | KYNU (0.58) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL7810070 | 0.88 | CA2 (0.61) | CASP1PPARAPPARGCA2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6229041-B1 | COUPLING CYSTEINE WITH COPPER OR COPPER OXIDE TO GENERATE METAL-AMINO COMPLEX, THEN CONTACTING WITH ARYL-HALIDE TO PRODUCE 3-ARYL-CYSTEINE; XENOBIOTIC METABOLIC PATHWAYS; TARGETTING HIV VIRUS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-08 | — | — | US | claimed |
| JP-11335351-A | — | — | None | — | — | JP | disclosed |
| JP-10029973-A | — | — | None | — | — | JP | disclosed |
| JP-10324673-A | — | — | None | — | — | JP | disclosed |
| JP-10025274-A | — | — | None | — | — | JP | disclosed |
| JP-10316644-A | — | — | None | — | — | JP | disclosed |
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| US-5475136-A | Inhibitors of HIV protease useful for the treatment of AIDS | ELI LILLY AND COMPANY (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995032185-A1 | N-(3-AMINO-2-HYDROXYBUTYL)SULPHONAMIDE DERIVATIVES AS HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-11-30 | — | — | WO | disclosed |
| US-5461154-A | HIV protease inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1995021164-A1 | INTERMEDIATE AND PROCESS FOR MAKING | ELI LILLY AND COMPANY (US) | 1995-08-10 | — | — | WO | disclosed |
| US-5434265-A | Inhibitors of HIV protease | ELI LILLY AND COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0609625-A1 | Inhibitors of HIV protease useful for the treatment of AIDS | ELI LILLY AND COMPANY (US) | 1994-08-10 | — | — | EP | disclosed |
| EP-0604185-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0604183-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187531-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | CASP1 118/4885PPARA 2112/4885PPARG 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.